Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Solid Tumors
Interventions: DF6002, Nivolumab; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 21
States / cities: Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more

Conditions: Advanced Solid Tumors
Interventions: Avelumab, M9241, Avelumab (Once weekly), M9241 (MTD), Avelumab (Expansion cohort); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: San Diego, California • Santa Rosa, California • New Haven, Connecticut + 13 more

Conditions: Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL)
Interventions: AMG 562; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Baltimore, Maryland + 4 more

Conditions: Adenocarcinoma Pancreas
Interventions: Surgery, Genetic Expression, Chemotherapy; Procedure · Genetic · Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: No Condition
Interventions: Connection to community services through case management, TOGETHER Workshop, Employment Support Services; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: College Park, Maryland • Gaithersburg, Maryland • Falls Church, Virginia

Conditions: Overweight or Obesity, Healthy
Interventions: LY4064912, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Los Alamitos, California • San Antonio, Texas

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Acute Lymphoblastic Leukemia
Interventions: CMC-544 (Inotuzumab Ozogamycin), Rituximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Low-back Pain
Interventions: PainGuide, MBSR, PT and exercise, Self -administered acupressure, Duloxetine, Pro-Diary monitor; Behavioral · Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 70 Years
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions: MCLA-117 bispecific antibody; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Acute Leukemia
Interventions: Exercise; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obstructive Sleep Apnea, Obesity
Interventions: Laparoscopic Gastric Banding, Continuous Positive Airway Pressure; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Diseases
Interventions: Program A, Program B; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 75 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Brockport, New York • Canandaigua, New York • Hornell, New York + 1 more

Conditions: Colorectal Carcinoma, Lynch Syndrome
Interventions: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more

Conditions: Wellness, Self Compassion, Burnout, Anxiety, Depression
Interventions: App-based bundled mental fitness intervention, App-based wellness module collection; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Salt Water, ASEA water; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Healthy Volunteer
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions: Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms; Other
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia, AML, ALL, CML
Interventions: STA-9090 (ganetespib); Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Tampa, Florida • Baltimore, Maryland • Durham, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 10 more

Conditions: Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions: Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose; Drug
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more

Conditions: Neural Tube Defects, Folic Acid Deficiency, Fortification
Interventions: Salt with folic acid and iodine; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Solid Tumor
Interventions: BNT151; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: New Haven, Connecticut • Nashville, Tennessee • Houston, Texas + 1 more

Search by objective public record fields.

A Study of DF6002 Alone and in Combination With Nivolumab

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas

TOGETHER: A Couple's Model to Enhance Relationships and Economic Stability

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

The Back Pain Consortium Research Program Study

MCLA-117 in Acute Myelogenous Leukemia

Exercise and Quality of Life in Leukemia Patients

Apnea, Bariatric Surgery Versus Continuous Positive Airway Pressure (CPAP) Trial

Chronic Kidney Disease-Education (CKD-EDU)

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

A Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion

Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans

Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

Study of Default Options in Advance Directives

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Feasibility, Acceptability and Directional Signal Effect on Blood Folate Levels of Iodized Salt Fortified With Folic Acid: Clinical Study

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors